Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Zippia finds jobs where you're a top candidate and applies on your behalf.
Aegerion Pharmaceuticals received early financing of $22.5M on 2006-06-13.
| Series | Round size | Date |
|---|---|---|
| Series A | $22.5M | 06/2006 |
| Series B | $17.6M | 11/2007 |
| Convertible Note | $3.8M | 09/2008 |
| Series Unknown | $18.3M | 06/2010 |
| Series Unknown | $1.5M | 10/2010 |
| Investors | Security type |
|---|---|
| Advent International | Series A |
| Index Ventures | Series A |
| Alta Partners | Series A |
| MVM Life Science Partners | Series A |
| Advent International | Series B |
| Index Ventures | Series B |
| Scheer Partners Investments | Series B |
| Alta Partners | Series B |
| Advent International | Convertible Note |
| Index Ventures | Convertible Note |
| Scheer Partners Investments | Convertible Note |
| Alta Partners | Convertible Note |
Aegerion Pharmaceuticals's top competitor, Pfizer, earned an annual revenue of $63.6B.
Aegerion Pharmaceuticals's smallest competitor is HealthSTAR Communications with revenue of $110.0M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Pfizer | $70,868 | $63.6B | 78,500 | 518 |
| Vertex Pharmaceuticals | $95,952 | $11.0B | 3,400 | 298 |
| AstraZeneca | $112,988 | $25.9B | 76,100 | 420 |
| Bristol-Myers Squibb | $101,824 | $48.3B | 30,000 | 2,382 |
| Eli Lilly and Company | $100,905 | $45.0B | 33,625 | 822 |
| HealthSTAR Communications | $70,658 | $110.0M | 620 | 2 |
Zippia gives an in-depth look into the details of Aegerion Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Aegerion Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Aegerion Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Aegerion Pharmaceuticals. The data presented on this page does not represent the view of Aegerion Pharmaceuticals and its employees or that of Zippia.
Aegerion Pharmaceuticals may also be known as or be related to AEGERION PHARM, AEGERION PHARMACEUTICALS, INC., Aegerion Pharmaceuticals, Aegerion Pharmaceuticals Inc. and Aegerion Pharmaceuticals, Inc.